Price
No data yet.
Social Signal Score
Analyst Ratings
39 analystsRevenue
$7.16M+27.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Leonard
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 377
- Beta
- 1.82
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -2.55
Financials
Revenue
$7.16M+27.3%Net Income
$-127.48MEBITDA
$-126.87MFree Cash Flow
$-86.32MEPS (diluted)
$-0.91Shares Outstanding (diluted)
140.19M+306.3%Operating Expenses
$129.49MCash & Debt
$474.11MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $67.67M | $-412.69M | $-3.81 |
| 2024 | $57.88M | $-519.02M | $-5.25 |
| 2023 | $36.27M | $-481.19M | $-5.42 |
| 2022 | $52.12M | $-474.19M | $-6.16 |
| 2021 | $33.05M | $-267.89M | $-3.78 |
| 2020 | $57.99M | $-134.23M | $-2.40 |
| 2019 | $43.10M | $-99.53M | $-1.96 |
| 2018 | $30.43M | $-85.34M | $-1.98 |
| 2017 | $26.12M | $-67.54M | $-1.88 |
| 2016 | $16.48M | $-31.63M | $-0.91 |
| 2015 | $6.04M | $-12.40M | $-0.70 |
| 2014 | $0.00 | $-14.31M | $-1.39 |
Valuation
NTLAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
138+175.00%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·16d ago·Neutral
…, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean safety profile, positioning NTLA as a transformative one-time treatment in a crowded, high-cost market. Commercial success hinges on payer acceptance, physician adoption, and pricing strategy, with initial revenues likely modest but long-term potential significant if approved.
View source ↗ - Newszacks.com·16d ago·Negative
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
View source ↗ - Newszacks.com·17d ago·Negative
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…. 18 to include up to four years of follow-up data in patients with ATTRv-PN CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it will present new clinical data at two medical meetings in November.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
…an Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16 in…
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Intellia Therapeutics Appoints Jing L. Marantz, M.D. CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 2…
View source ↗ - Newszacks.com·44d ago·Neutral
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.75 per share
Typical surprise +9.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.91 vs $-0.80miss
- Thu, Aug 6$-0.80 vs $-0.80miss
- Mon, May 11$-0.81 vs $-0.92beat
- Thu, Feb 26$-0.83 vs $-0.99beat
- Thu, Nov 6$-0.92 vs $-1.02beat
- Thu, Aug 7$-0.99 vs $-1.03beat
Estimates and results for NTLA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NTLA officers and directors.
- Bought
- $2.4m
- Sold
- $2.5m
2 trades
30 trades
- Leonard John Msold
- Dube Michael Psold
- Leonard John Msold
- Leonard John Msold
- Dulac Edward J Iiisold
- Dulac Edward J Iiisold
- Dube Michael Psold
- Basta Jamessold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Richard Carpersenate · DE · disclosed Sep 5, 2023 (11d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Jun 30, 2023 (39d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Mar 3, 2022 (3d later)Sell$15,001 - $50,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Oct 30, 2021 (1d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Oct 1, 2021 (11d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Aug 7, 2021 (17d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (178d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 31, 2021 (16d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 2, 2020 (12d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Dec 1, 2020 (13d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Sep 6, 2020 (11d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Aug 9, 2020 (30d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 22, 2020 (39d later)Buy$1,001 - $15,000
- James Mountain Inhofesenate · OK · disclosed Nov 8, 2018 (14d later)Sell$15,001 - $50,000
- James Mountain Inhofesenate · OK · disclosed Nov 8, 2017 (20d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
